1 Controversy, the JNC-8 Hypertension Guidelines Christopher J. Cooper, M.D., FACC, FACP Dean and Senior Vice President University of Toledo, College of Medicine Acknowledge assistance of Kevin Kun Xiang, M.D., Ph.D., Year 3 UT Cardiology Fellow, for substantial contribution on this talk.
2 JNC 7 published in 2003.
3 National Heart, Lung, and Blood Institute (NHLBI) formed JNC 8 in March Panel members selected from >400 nominees: hypertension (14) primary care (6) geriatrics (2) cardiology (2) nephrology (3) nursing (1) pharmacology (2) clinical trials (6) evidence-based medicine (3) epidemiology (1) informatics (4) clinical guidelines (4).
4 The Process of JNC 8 In January 2013, JNC 8 submitted for external peer review by NHLBI to 20 reviewers and 16 federal agencies. 16 individual reviewers and 5 federal agencies responded. Comments reviewed and discussed from March through June 2013 and incorporated into a revised document.
5 The Process of JNC 8 In June 2013, NHLBI announced it would discontinue developing clinical guidelines including those in process. The JNC-8 writing group declined partnership with AHA/ACC and pursued publication independently to bring recommendations to the public. JNC 8 report was published in JAMA in December 2013.
6 Evidence Review Literature search were January 1, 1966, through December 31, 2009 and then Dec 2009 to August Evidence limited to randomized controlled trials, systematic reviews and meta-analyses not included.
7 QUESTIONS GUIDING THE EVIDENCE REVIEW 1. Threshold: Does initiating antihypertensive treatment at specific BP thresholds improve health? 2. Goal: Does treatment with antihypertensive treatment to a BP goal improve health? 3. Choice: Do specific drugs or drug classes differ in benefits and harms on specific health outcomes?
8 The Evidence Review Studies were included if they reported: Overall mortality, cardiovascular disease (CVD) related mortality, CKD-related mortality Myocardial infarction, heart failure, hospitalization for heart failure, stroke. Coronary and peripheral revascularization. End-stage renal disease (ESRD), doubling of creatinine, halving of glomerular filtration rate (GFR).
9 The Inclusion Criteria 1. Major study in hypertension 2. At least 2000 participants 3. Multi-centered 4. Met all inclusion/exclusion criteria
10 Evidence Quality Rating
11 Strength of Recommendation
12 From JNC 7 to JNC 8: What's Changed JNC uses randomized trials, and is explicit when a recommendation reflects only expert opinion. JNC 8 raises the systolic threshold to 150 mmhg at age 60. JNC 8 uses 140/90 for patients with diabetes or chronic kidney disease. In JNC 8, the initial drug choice is broadened to four classes for nonblack patients and two classes for black patients. β- blockers are no longer recommended for initial therapy because of less stroke protection.
13 RECOMMENDATIONS Recommendations 1-5 address questions 1 & 2 concerning thresholds and goals for BP treatment. Recommendations 6, 7, 8 address question concerning selection of antihypertensive drugs. Recommendation 9 is a summary of strategies based on expert opinion for starting and adding antihypertensive drugs
14 Thresholds and Goals Recommendations 1-5
15 Recommendation 1 General population aged 60 years or older Initiate Treatment at: SBP 150 mmhg Or DBP 90mmHg Goal of Treatment: SBP <150 mmhg OR DBP of < 90mmHg. Strong Recommendation Grade A
16 Recommendation 1: BP goal of 150 mmhg at age 60 Acknowledged lack of unanimity in the recommendation for the 150 mmhg threshold in people 60. the 140/90 mm Hg definition from JNC 7 remains reasonable. If treatment results in SBP <140 mm Hg and is well tolerated and without adverse effects treatment does not need to be adjusted. (Expert Opinion Grade E)
17 Five of 14 members of the JNC 8 writing team released a minority report, protesting 150 mmhg BP goal. insufficient to increase the systolic BP goal from <140 mm Hg because of concern that increasing the goal may cause harm by increasing the risk for cardiovascular disease and partially undoing the remarkable progress...
18 Systolic Hypertension in the Elderly 4736 persons, aged 60 Program (SHEP) SBP mm Hg and DBP <90 mm Hg. Chlorthalidone mg, or atenolol, 25 mg. 5-year mean BP 155/72 mm Hg in placebo and 143/68 mm Hg in treatment. Reduced strokes by 36%, with 5-year absolute benefit of 3 events per 100 and cardiovascular events by 5.5 events per 100. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):
19 Syst-Eur Trial 4965 patients >60 years Nitrendipine mg, or enalapril 5-20 mg and hydrochlorothiazide mg daily. Stroke 42%, p=0.003 Sudden death 26%, p=0.03 Non-fatal cardiac 33%, p=0.03 Fatal + non-fatal CV events 31%, p < 0.001
20 3845 patients 80 years SBP >160 mmhg Indapamide sustained release 1.5 mg and perindopril 2-4 mg or placebo. HYVET Trial 30% stroke, P=NS 39% stroke death P= % all-cause mortality, P= % CV death, P= % heart failure, P<0.001
21 9800 Chinese patients aged years. Initial BP systolic or mmhg diastolic Felodipine decreased BP 154.2/91.0 to 137.3/82.5 mmhg Placebo group from 154.4/91.3 to 142.5/85.0 Difference of 4.2/2.1 mmhg. FEVER Trial
22 JATOS Trial Randomized to SBP < 140 mmhg vs mmhg Population: 4418 patients years old Systolic >160 mmhg No benefit of <140 mmhg goal
23 Valsartan in Elderly Systolic Hypertension Study BP <140 vs. moderate BP mm Hg 3260 Japanese patients aged 70 to 84 years. Valsartan plus other class meds. No benefit of <140 mmhg goal
24 Recommendation 2 General population < 60 years Initiate Treatment at: DBP 90mmHg Goal of Treatment: DBP of < 90mmHg. For ages years, Strong Recommendation Grade A For ages years, Expert Opinion Grade E
25 Recommendation 3 General population < 60 years Initiate Treatment at: SBP 140 mmhg Goal of Treatment: SBP of < 140 mmhg. Expert Opinion Grade E
26 Recommendation 4 Population aged 18 years or older with CKD Initiate Treatment at: SBP 140 mmhg Or DBP 90 mmhg Goal of Treatment: SBP < 140 mmhg Or DBP < 90 mmhg Expert Opinion Grade E
27 Recommendation 5 Population aged 18 years or older with diabetes Initiate Treatment at: SBP 140 mmhg Or DBP 90 mmhg Goal of Treatment : SBP < 140 mmhg Or DBP < 90 mmhg Expert Opinion Grade E
28 Selection of Anti-hypertensive Drugs Recommendations 6-8
29 Recommendation 6: Initial drug choice General nonblack population (including diabetes) Initiate any of the following: Thiazide-type diuretic Calcium channel blocker (CCB) Angiotensinconverting enzyme inhibitor (ACEI) Angiotensin receptor blocker (ARB) Moderate Recommendation Grade B
30 Recommendation 7: Initial drugs in blacks General black population (including diabetes) Initiate any of the following: Thiazide-type diuretic Calcium channel blocker (CCB) For general black population: Moderate Recommendation Grade B For black patients with diabetes: Weak Recommendation Grade C
31 Recommendation 8: initial drugs and CKD All CKD patients with hypertension regardless of race or diabetes status Initiate one of the following: Angiotensinconverting enzyme inhibitor (ACEI) Angiotensin receptor blocker (ARB) For general black population: Moderate Recommendation Grade B for black patients with diabetes: Weak Recommendation Grade C
32 Evidence-Based Dosing
33 Opinion for Starting & Adding Drugs Recommendation 9
34 Recommendation 9: adding drugs If goal BP is not reached within a month of treatment: increase the dose of the initial drug OR Add a second drug from one of the classes in recommendation 6 (thiazide-type diuretic, CCB, ACEI, or ARB). Assess BP and adjust the treatment until goal is reached. Expert Opinion Grade E
35 Recommendation 9: adding drugs If goal BP cannot be reached with 2 drugs: Add and titrate a third drug. Do not use an ACEI and an ARB together in the same patient. If goal BP cannot be achieved combinations of ACE/ARB, thiazide, or CCB, then drugs from other classes can be used. Expert Opinion Grade E
36 From JNC 7 to JNC 8: What's Changed JNC uses randomized trial evidence, and is explicit when a recommendation reflects only expert opinion. JNC 8 raises the systolic threshold to 150 mmhg at age 60. JNC 8 uses 140/90 for patients with diabetes or chronic kidney disease. In JNC 8, the initial drug choice is broadened to four classes for nonblack patients and two classes for black patients. β- blockers are no longer recommended for initial therapy because of less stroke protection.
38 Comparison of Hypertension Guidelines Treat if BP 140/90 mm Hg except in NICE and JNC 8. Beta-blocker is not an first-line for patients without coronary artery disease except ESH. Several emphasize superiority of chlorthalidone or indapamide over thiazide diuretics, and loop diuretics reserved for heart failure or chronic kidney disease. Most agree with initial two drugs treatment if BP is 160/100 mm Hg.
39 Cont d Comparison of Hypertension Guidelines BP target of <140/90 mm Hg, but four guidelines propose higher targets for the elderly. Definitions of the elderly vary. In NICE and ASH/ISH guidelines, age 80 years and in JNC 8, age 60 years, both with target of <150/90 mm Hg.
40 My Conclusion (opinion) JNC 8 has changed treatment, a little bit It provides clinicians more flexibility: Now there are four first line drugs For patients over 60, treatment at 140 or 150 mmhg Goal for diabetes and chronic kidney disease now 140/90 I am especially appreciative of those who helped with this talk, especially Kevin Kun Xiang, M.D., Ph.D.
What is Controversial about Hypertension Management? JNC 8 Guidelines: key new aspects What is new and what is controversial? Financial Disclosures Gabriel B. Habib, MD In the context of my participation
NATIONAL CLINICAL PRACTICE GUIDELINES Adult Hypertension Clinical Practice Guidelines Reviewed/Approved by the National Guideline Directors: March 2016 Next Review/Approval: March 2018 Developed by the
Blood Pressure: Thresholds and Treatment Professor Neil Poulter ICCH, Imperial College London, UK BHS Primary Care Meeting, London May 17 2011 Management of hypertension: the issues Measurement Classification
JNC 8: Relaxing the Pressure in the Hypertension Guidelines Ashley Lawrance, Pharm.D. PGY1 Pharmacy Practice Resident Peninsula Regional Medical Center Salisbury, MD Learning Objectives Describe updated
THE APPROACH TO OPTIMAL BLOOD PRESSURE CONTROL IN GENERAL PRACTICE Dr Mohd Nasir Muda Updates in Management of Cardiovascular Diseases for the Primary Care Physician 6 April 2014 Clinical Workflow Accurately
Hypertension Guidelines 6 Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center Speaker Disclosures I disclose that I am a Consultant for: Ablative
MANAGEMENT of HYPERTENSION R. Michael Culpepper, M.D. University of South Alabama DISCLOSURE Any Drug or Product Mentioned in this Discussion is Purely Illustrative and not a Commercial Endorsement All
36 th Autumn Congress of Korean Diabetes Association 2010 Impact of Recent Clinical Trials on the Management of Cardiovascular Disease in Diabetes; Blood Pressure control Kim Sin Gon. MD, PhD Associate
Hypertension Management: JNC 8 s Evidence and Recommendations Faculty Disclosures Annual Review in Family Medicine 2014/ San Francisco Quynh Bui Relevant financial relationships with a commercial interest:
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
Choosing Wisely: Hypertension Management by Guidelines and Hypertension Study Update Rex D. Wilford, D.O., FACP, R.Ph. Core Faculty Summa Internal Medicine Residency Hypertension and the Choosing Wisely
College of Pharmacy and Nutrition University of Saskatchewan Saskatoon SK S7N 5C9 www.medsask.usask.ca Vol. 31, No. 2 April 2014 Watch for Potential Changes in Canada s Current Hypertension and Dyslipidemia
Supplementary Online Content James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report by the panel appointed to the Eighth Joint National
Hypertension a timeless problem with new frontiers A. Oussama Rifai, MD Vice President of Medical Affairs The Virtual Nephrologist, Inc. Hypertension at a glance The number one modifiable risk factor for
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) Family Medicine Refresher Course
Hypertension The New Guidelines Craig A Shadur, MD March 2015 Clinical Case 44 year old AA gentleman referred for hypertension Discovered on routine PE with BP 164/102 History of obesity, THC usage, GERD
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Hypertension Clinician Guide Introduction MARCH 2016 This Clinician Guide is based on the 2016 KP National Hypertension Guideline. It was developed
KP National Adult Guideline CLINICIAN GUIDE AUGUST 2014 Introduction This Clinician Guide is based on the 2014 KP National Guideline. It was developed to assist Primary Care physicians and other health
Treatment of Hypertension in Patients on Hemodialysis Hermann Haller Department of Nephrology Hannover Medical School Blood pressure treatment - conventional wisdom in ESRD patients Salt??? Changes over
Current Strategies in Hypertension: Getting Ready for JNC 8 Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Summary of Presentation
Improving Medical Statistics and Interpretation of Clinical Trials 1 ALLHAT Trial & ALLHAT Meta-Analysis Critique Table of Contents ALLHAT Trial Critique- Overview p 2-4 Critique Of The Flawed Meta-Analysis
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) Adapted by Capital Health Plan Approved by Quality Improvement
JNC 8 BLOOD PRESSURE GUIDELINES Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular Biology and Hypertension Program of the
Current Strategies in Hypertension: Getting Ready for JNC 8 Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Summary of Presentation
European Heart Journal (2000) 21, 2 7 Article No. euhj.1999.1833, available online at http://www.idealibrary.com on Hotline Editorial Dihydropyridine calcium-channel blockers for the treatment of hypertensive
NATIONAL CLINICAL PRACTICE GUIDELINES Hypertension Clinical Practice Guidelines These guidelines are informational only. They are not intended or designed as a substitute for the reasonable exercise of
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Elhami et al. SJIF Impact Factor 5.210 Volume 4, Issue 11, 1159-1166 Research Article ISSN 2278 4357 DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE
Betablocker Therapy for Hypertensive African Americans 5 th Annual National Summit on Health Disparities,4/14-15/08 Elijah Saunders,M.D.,FACC,FACP Professor of Medicine(Cardiology) University of Maryland
Both Amiloride and Nebivolol Have a More Favourable Effect on Glucose Tolerance Than Hydrochlorothiazide in the Treatment of Essential Hypertension Stears AJ, Woods SH, Watts MM, Graggaber J, Burton TJ,
Hypertension and Diabetes C.W. Spellman, D.O., Ph.D., FACOI Professor & Associate Dean Research Dir. Center Diabetes & Metabolic Disorders Texas Tech University Health Science Center Midland-Odessa, Texas
Hypertension and its management Indranil Dasgupta Consultant Nephrologist, Heartlands Hospital Honorary Senior Lecturer, University of Birmingham, UK Differing influence of hypertension on absolute and
High Blood Pressure in Context Dr Yassir Javaid GP Northampton Primary Care CVD lead EMSCN Premature Deaths by Cause in UK, 2012 Men Women Cardiovascular Disease Statistics, 2014 British Heart Foundation
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
Network Guidance Document Guidelines for Bevacizumab Induced Hypertension Status: Expiry Date: Version Number: Publication Date: Final November 2015 1 October 2011 (reviewed November 2013) Guidelines for
Hypertension - Complications and Social Impact Dr. Ho Hung Kwong, Duncan MBBS(HK), MRCP(UK), FHKAM(Med), FHKCP, FRCP(Edin) FAHA, FSCAI Specialist in Cardiology 何鴻光 Definition and classification of hypertension:
Guideline for the diagnosis and management of hypertension in adults - 2016 2016 National Heart Foundation of Australia Guideline Aim To provide health professionals with the latest evidence for controlling
Hypertension An 2006 update on how to choose and prescript the best medications for our patients Dr. Wong Bun Lap Bernard Definition and classification of hypertension: ESH/ESC 2003 Hypertension is defined
Truisms What We All Think We Know About High Blood Pressure May Not Be True BP thresholds and targets in the treatment of hypertension. An evidence-based approach Montreal April 2015 James (Jim) Wright
CHRONIC KIDNEY DISEASE PRACTICE GUIDELINES Reviewed and approved 5/2014 Risk Chronic kidney disease is defined as either kidney damage or decreased kidney function (decreased GFR) for 3 or more months.
Hypertension Management Seminar executive summary Dr C P Ho 20060204 Definition and classification of hypertension: JNC VII Hypertension is defined as blood pressure 140/90 mmhg Category Normal Systolic
Table e-1. A list of antihypertensive drugs and their ATC codes Antihypertensive drug class ATC Codes Combinations 1. Alpha-receptor blockers C02 CA - 2. Beta-blockers C07A C07F 3. Calcium channel blockers
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
Date of issue: December 2011 Written by Sara Wilds & Kathryn Buchanan Prescribing Points A NEWSLETTER FOR ALL HEALTH CARE PROFESSIONALS IN OXFORDSHIRE, WRITTEN BY THE MEDICINES MANAGEMENT TEAM, OXFORDSHIRE
Hypertension Management: Making Sense of Guidelines and Therapy Options for the Elderly Corresponding Author: Miranda Arthur, PharmD PGY1 Pharmacy Resident IU Health Bloomington 601 W. 2 nd Street Bloomington,
JNC 8 Update on Hypertension Guidelines Alan Cementina, MD Associate Clinical Professor Family Medicine Center at Asylum Hill DISCLOSURE I have not had nor do I currently have any financial relationships
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Hypertension Clinician Guide Introduction November 2016 This Clinician Guide is based on the 2016 KP National Hypertension Guideline. It was
IS A LOWER BP BETTER IN DKD? George L. Bakris, MD, F.A.S.N. Professor of Medicine University of Chicago Medicine Disclosure of Interests Investigator Initiated Grant/Research Support- TAKEDA (direct funding
Chronic Kidney Disease: Proposed Revisions to the ICD-9-CM Classification Lesley Stevens MD Tufts-New England Medical Center National Kidney Foundation Objectives Kidney Failure Stages of Chronic Kidney
1 Quiz 1 hypertension answers The correct answers to questions are indicated by *. All students were awarded 2 points for question #3 due answer b being misleading. The answer should have read b. calcium
Special Considerations in the Management of Blood Pressure in the Frail Elderly M. ANNE MONAHAN, MA, MD, CCFP, COE, BRUYERE GERIATRIC DAY HOSPITAL, BRUYERE CONTINUING CARE Objectives/Overview of Presentation
Quality and Outcomes Framework Programme NICE cost impact statement July 2011 Indicator area: Peripheral arterial disease Indicators NM32 The practice can produce a register of people with peripheral arterial
Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk Silvio E Inzucchi, Christoph Wanner, John M Lachin, David Fitchett, Stefan Hantel, Michaela
Helen Williams Consultant Pharmacist for CVD, South London Key aims of management prolong life delay disease progression improve symptoms and quality of life Risk factor advice : smoking cessation, exercise,
1 NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Guideline title SCOPE Hypertension: clinical management of primary hypertension in adults 1.1 Short title Hypertension (partial update) 2 The remit
Evidence Based Practice Guidelines on the Treatment of Hypertension David Stewart, Pharm.D., BCPS Assistant Professor, Pharmacy Practice firstname.lastname@example.org Objectives: After this program, the audience should
RESEARCH ARTICLE STUDY OF UTILIZATION PATTERN OF ANTI-HYPERTENSIVE DRUGS IN HYPERTENSIVE DIABETIC PATIENTS WITH OR WITHOUT REDUCED RENAL FUNCTION AT TERTIARY CARE TEACHING HOSPITAL Jay Shah 1, Tejas Khakhkhar
1 de 6 03/11/2008 13:26 First-line medicines in the treatment of hypertension Suzanne R. Hill and Anthony J. Smith, School of Medical Practice and Population Health, University of Newcastle, Newcastle,
HYPERTENSION What is blood pressure? Blood pressure is the force required to circulate blood throughout the body. As the heart contracts, the pressure within the blood vessels rises to a maximum or top
The Wait is Over: Updated Guidelines for Cholesterol, Diabetes, and Blood Pressure Kisha O Neal Gant, BS, PharmD, BCACP, CGP Clinical Assistant Professor Xavier University of Louisiana Louisiana Pharmacists
COMMENTARY Special Focus Issue on Hypertension Guidelines Recently Published Hypertension Guidelines of the JNC 8 Panelists, the American Society of Hypertension/International Society of Hypertension and
A Randomized Multicenter Clinical Trial of Renal Artery Stenting in Preventing Cardiovascular and Renal Events: Results of the CORAL Study Christopher J. Cooper, M.D., Timothy P. Murphy, M.D., Donald E.
Recent and Future Advances in the treatment of Chronic Systolic Heart Failure 2016 death Mechanisms of Progression in Heart Failure Myocardial or vascular stress or injury Increased activity or response
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes Follow-On Blood Pressure Study (ACCORDION)
02.Layout 1/14/10 3:50 PM Page 1 Management of Hypertension (3 rd Edition) Quick Reference for Health Care Providers Ministry of Health Malaysia Academy of Medicine of Malaysia Malaysian Society of Hypertension
Malaysian Clinical Practice Guideline on Hypertension 2014 What s New, What s Entrenched? Abdul Rashid Abdul Rahman On Behalf of CPG Working Group Prevalence of CV RISK factors in Malaysia - What s New
CHRONIC KIDNEY DISEASE (CKD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN THE CHRONIC KIDNEY DISEASE (CKD) MEASURES GROUP: #110. Preventive Care and Screening: Influenza
Reviewing the Different Guidelines for BP Control: 2015 59 th Annual Postgraduate Seminar Embassy Suites Hotel Greenville, South Carolina Wednesday April 22, 2015 Jan Basile, MD Seinsheimer Cardiovascular
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Expands Finerenone Clinical Development Programme with Three Phase III
Medicines Management Programme Preferred Drugs Calcium Channel Blockers (dihydropyridine derivatives) for the treatment of hypertension and stable angina Approved by Prof. Michael Barry, Clinical Lead,
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Behanan et al. SJIF Impact Factor 6.041 Volume 5, Issue 10, 1534-1540 Research Article ISSN 2278 4357 DRUG UTILIZATION STUDY OF ANTIHYPERTENSIVE MEDICATIONS
Indapamide sustained release: Effective first step antihypertensive therapy Patwary MSR The ORION Medical Journal 2007 Jan; 26:419-421 Introduction Hypertension is a worldwide epidemic, one billion hypertensive